Clinical Trial Update: Monalizumab and MEDI5752 in Patients With MSI and/or dMMR Metastatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of Monalizumab and MEDI5752 in MSI/dMMR metastatic colorectal cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• MEDI5752
• Monalizumab (monalizumab)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: MSI, dMMR Colorectal Cancer | Phase 2 | Status: WITHDRAWN